Zyrifa 120 Injection 1.7 ml

Zyrifa 120 Injection 1.7 ml belongs to a group of medicines called RANK ligand inhibitors used to treat osteoporosis in postmenopausal women and men who have an increased risk of fracture. Zyrifa 120 Injection 1.7 ml is also used to treat bone loss due to reduced testosterone level caused by surgery, due to the treatment with medicines such as glucocorticoids and in patients with prostate cancer. Zyrifa 120 Injection 1.7 ml may also be used to reduce the risk of fractures in people with multiple myeloma, giant cell tumour of the bone, and to treat high calcium levels caused by cancer.
 
Zyrifa 120 Injection 1.7 ml contains Denosumab, which works by blocking a receptor in the body that causes bone loss, thereby treating bone loss. Zyrifa 120 Injection 1.7 ml treats giant cell tumour of bone (GCTB) by blocking certain receptors in the tumour cells, thereby slowing the growth of the tumour. Zyrifa 120 Injection 1.7 ml helps treat high calcium levels by decreasing bone breakdown, as a breakdown of the bones releases calcium. Zyrifa 120 Injection 1.7 ml makes the bones stronger and less likely to break.
 
Zyrifa 120 Injection 1.7 ml will be administered by a healthcare professional; do not self-administer. Sometimes, you may experience common side effects such as bone/joint/muscle pain, arm/leg pain, abdominal discomfort, constipation, and painful/frequent urination. You should talk to your doctor if the side effects persist or worsen.
 
Zyrifa 120 Injection 1.7 ml might cause jaw osteonecrosis; therefore, maintain good dental hygiene and receive regular dental check-ups whilst on treatment with Zyrifa 120 Injection 1.7 ml. Avoid taking Zyrifa 120 Injection 1.7 ml if you are pregnant. Consult your doctor before taking Zyrifa 120 Injection 1.7 ml if you are breastfeeding. Zyrifa 120 Injection 1.7 ml is not recommended for children below 18 years as safety and effectiveness have not been established. To rule out any interactions, keep your doctor informed about your health condition and medicines.

Zyrifa 120 Injection 1.7 ml used to treat osteoporosis, bone loss, giant cell tumour of the bone, and high calcium levels. The detailed uses of Zyrifa 120 Injection 1.7 ml are as follows:

• Management of Osteoporosis: Zyrifa 120 Injection 1.7 ml treats osteoporosis in postmenopausal women, increasing bone density and reducing fracture risk.
• Giant cell tumour of the bone treatment: Zyrifa 120 Injection 1.7 ml is prescribed for the treatment of giant cell tumour of the bone, which helps by reducing tumour size and slowing its growth.
• Increases bone mass: Zyrifa 120 Injection 1.7 ml increases bone mass in patients at high risk for fracture, including those undergoing androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer.
• Hypercalcemia Treatment: Zyrifa 120 Injection 1.7 ml treats hypercalcemia caused by cancer, helping normalise calcium levels in the blood.
• Paget’s Disease: Zyrifa 120 Injection 1.7 ml treats Paget’s disease by alleviating bone pain and complications caused by enlarged and deformed bones.

• Your doctor will determine the dosage and timing of Zyrifa 120 Injection 1.7 ml based on your health condition. Usually, it is given once every 6 months.
• Zyrifa 120 Injection 1.7 ml is administered subcutaneously (under the skin) in your upper arm, upper thigh, or stomach area by the doctor or nurse in a hospital setting.
• Do not self-administer it.

Zyrifa 120 Injection 1.7 ml belongs to a group of medicines called RANK ligand inhibitors used to treat osteoporosis in postmenopausal women and men who have an increased risk of fracture. Zyrifa 120 Injection 1.7 ml is also used to treat bone loss due to reduced hormone levels caused by surgery or due to treatment with medicines in patients with prostate cancer. It is also used to treat bone loss occurring due to long-term treatment with glucocorticoids in patients who are at an increased risk of fractures. Zyrifa 120 Injection 1.7 ml may also be used to reduce the risk of fractures in people with multiple myeloma, giant cell tumours of the bone and to treat high calcium levels caused by cancer. Zyrifa 120 Injection 1.7 ml binds to a protein on RANK ligand on osteoclast (cells that cause bone breakdown) and inhibits their formation, functioning and survival. It decreases bone breakdown, increases bone density, and strengthens the bone. Zyrifa 120 Injection 1.7 ml treats giant cell tumour of bone (GCTB) by blocking certain receptors in the tumour cells, thereby slowing the growth of the tumour. Zyrifa 120 Injection 1.7 ml helps treat high calcium levels by decreasing bone breakdown, as the breakdown of the bones releases calcium. Zyrifa 120 Injection 1.7 ml makes the bones stronger and less likely to break.

Do not take Zyrifa 120 Injection 1.7 ml if you are allergic to any of its components or have hypocalcaemia (low levels of calcium in the blood). Inform your doctor if you have low levels of calcium, kidney dysfunction, liver problems, poor dental health, gum problems, weak immune system, hypoparathyroidism (decreased function of the parathyroid gland), malabsorption, latex allergy, undergone thyroid surgery, planned dental procedure, if you are taking glucocorticoids, or cannot take calcium and vitamin D supplements. Avoid taking Zyrifa 120 Injection 1.7 ml if you are pregnant. Consult your doctor if you are breastfeeding. Zyrifa 120 Injection 1.7 ml is not recommended for children below 18 years as safety and effectiveness have not been established.